XuanZhu BioPharm And the chemical substance He announced a collaboration focusing on cancer, metabolism, digestion and other areas, to jointly develop new drugs with intellectual property rights.
In 2019, Chemical.AI closed Angel Round with FreeS Fund, and in early 2021, Series A Round led by Sequoia China Seed Fund, followed by Nest Bio Ventures and current shareholder FreeS Fund, later in August of that year, Series A+ Round led by Sequoia China Seed Fund Source Code Capital, followed by Sequoia China, FreeS Fund and Hofon Capital. Completing the three rounds within two years drove Chemical.AI to move forward to address the bottleneck in the industry. The company also announced its strategic cooperation with more than ten leading companies such as Livzon Medicine, Best Pharma in China, the largest Pharmaceutical in Europe, in the United States, and integration with Scilligence, NovAliX ChemAxon. With the new partnership with Xuanzhu BioPharm, this is another industry acknowledgment to Chemcal.AI and its product, ChemAIRS, an AI-assisted synthesis platform.
ChemAIRS is a chemical synthesis pathway design system based on artificial intelligence + big data, trained from chemists. There are four modules, Retrosynthesis, SA grades, Advanced Synthetics, and Process Chemistry. By integrating with ELN, the building blocks, ChemAIRS can learn from internal lab data and provide feasible and cost-effective methods accordingly, an important part of the lab’s digitization process.
Dr. Jiakui Li, CEO of Shandong Xuanzhu, a subsidiary of Xuanzhu BioPharm that focuses on small molecule drug discovery and development, commented, “We are excited to partner with Chemical.AI that helps us accelerate the drug discovery process. With ChemAIRS, it provides efficient methods and feasible to improve the efficiency of chemical synthesis. We are pleased with ChemAIRS in our research work.”
Dr. Ning Xia, founder and CEO of Chemical.AI concluded, “We are honored to work with Xuanzhu BioPharm, to accelerate and reduce DMTA cycle time with our machine learning-based product, ChemAIRS, by leveraging artificial intelligence and big data, to provide efficient synthetic pathway design. We look forward to working with XuanZhu to bring new medicines to market faster and faster to serve human well-being.”
In September, Chemical.AI will release the latest version of ChemAIRS to significantly improve the algorithm by providing more accurate predicted paths, faster computing time, and editable reaction conditions. Etc. Want to try ChemAIRS for yourself? Please go to the site https://www.chemical.ai/ Register with the promotion code CF41MT To redeem the one-month free trial.
Xuanzhu BioPharm has a number of biology companies covering drug discovery, preclinical research, clinical development, as well as production and sales team, in the whole industrial chain. After nearly ten years of operation, Xuanzhu has developed the ability to independently conduct new drug research and development, with two innovative platforms for small molecule medicines and large molecule medicines. In addition, Xuanzhu BioPharm significantly leads first-class drug development and is committed to being an innovative company with new drug research and manufacturing capabilities. For more information, please go to http://www.xuanzhupharm.com/
Founded in 2018, Chemical.AI is one of the leading technology companies that leverages artificial intelligence (AI) and big data to transform research and development to shape the future of chemistry. ChemAIRS core product enhances success rates in synthesis pathway design and prediction of diverse synthesis strategies. In 2021, Chemical.AI also set up an AIoT automation lab in Shanghai to assemble dry lab and wet lab together to provide more professional and efficient chemical manufacturing services to the industry. For more information, please go to https://www.chemical.ai/
Disclaimer: AAAS and EurekAlert! Not responsible for the accuracy of newsletters sent to EurekAlert! Through the contributing institutions or for the use of any information through the EurekAlert system.